echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Huadong Medicine: Subsidiary obtains an exclusive license agreement for the product under research SCO-094

    Huadong Medicine: Subsidiary obtains an exclusive license agreement for the product under research SCO-094

    • Last Update: 2021-06-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 1, Huadong Medicine announced that the company’s subsidiary Sino-American Huadong obtained the Japanese SCOHIA Phase I clinical product SCO-094 (a dual agonist of GLP-1R and GIPR targets for the treatment of type 2 diabetes, obesity, and non- Alcoholic steatohepatitis and other diseases) have exclusive development, production and commercialization rights in 25 Asia-Pacific countries and regions (excluding Japan) such as China, South Korea, Australia and so on.


    On June 1, Huadong Medicine announced that the company’s subsidiary Sino-American Huadong obtained the Japanese SCOHIA Phase I clinical product SCO-094 (a dual agonist of GLP-1R and GIPR targets for the treatment of type 2 diabetes, obesity, and non- Alcoholic steatohepatitis and other diseases) have exclusive development, production and commercialization rights in 25 Asia-Pacific countries and regions (excluding Japan) such as China, South Korea, Australia and so on.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.